M. H. Le

515 total citations
9 papers, 275 citations indexed

About

M. H. Le is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, M. H. Le has authored 9 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Hematology. Recurrent topics in M. H. Le's work include Multiple Myeloma Research and Treatments (3 papers), Cancer Treatment and Pharmacology (2 papers) and Protein Degradation and Inhibitors (2 papers). M. H. Le is often cited by papers focused on Multiple Myeloma Research and Treatments (3 papers), Cancer Treatment and Pharmacology (2 papers) and Protein Degradation and Inhibitors (2 papers). M. H. Le collaborates with scholars based in United States, Canada and France. M. H. Le's co-authors include V Le Doussal, G Riou, Michel Barrois, Martine George, Daniel J. Sargent, Rafaela L. Rego, M. J. OʼConnell, Harold E. Windschitl, Frank A. Sinicrope and Nathan R. Foster and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

M. H. Le

8 papers receiving 261 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. H. Le United States	6	140	91	60	55	55	9	275
Sumiko Okubo Japan	10	165 1.2×	116 1.3×	25 0.4×	36 0.7×	68 1.2×	25	296
Changxia Shao United States	11	177 1.3×	166 1.8×	59 1.0×	50 0.9×	80 1.5×	35	398
Teresa Staiano Italy	11	118 0.8×	77 0.8×	63 1.1×	29 0.5×	72 1.3×	19	289
Rika Kasajima Japan	10	133 0.9×	129 1.4×	41 0.7×	42 0.8×	90 1.6×	37	350
Isaya Hashimoto Japan	9	249 1.8×	181 2.0×	57 0.9×	27 0.5×	63 1.1×	32	494
Eleonora Zanetti Italy	10	80 0.6×	77 0.8×	26 0.4×	48 0.9×	31 0.6×	29	253
Masami Mitani Japan	8	220 1.6×	262 2.9×	87 1.4×	31 0.6×	98 1.8×	23	470
I. Sklenar Switzerland	13	94 0.7×	132 1.5×	40 0.7×	21 0.4×	16 0.3×	23	375
Danielle Shafer United States	12	151 1.1×	169 1.9×	39 0.7×	85 1.5×	45 0.8×	30	398
Haruyuki ANZAI Japan	9	100 0.7×	149 1.6×	31 0.5×	27 0.5×	75 1.4×	19	295

Countries citing papers authored by M. H. Le

Since Specialization

Citations

This map shows the geographic impact of M. H. Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. H. Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. H. Le more than expected).

Fields of papers citing papers by M. H. Le

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. H. Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. H. Le. The network helps show where M. H. Le may publish in the future.

Co-authorship network of co-authors of M. H. Le

This figure shows the co-authorship network connecting the top 25 collaborators of M. H. Le. A scholar is included among the top collaborators of M. H. Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. H. Le. M. H. Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Lee, Joo Young, Yu Jin Kim, Kon-Young Ji, et al.. (2025). Inula japonica Thunb. and its active compounds ameliorate airway inflammation by suppressing JAK-STAT signaling. Biomedicine & Pharmacotherapy. 183. 117852–117852. 3 indexed citations

2.

Vij, Ravi, David S. Siegel, Andrzej Jakubowiak, et al.. (2010). Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).. Journal of Clinical Oncology. 28(15_suppl). 8000–8000. 17 indexed citations

3.

Vij, Ravi, Sagar Lonial, Sundar Jagannath, et al.. (2010). Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).. Journal of Clinical Oncology. 28(15_suppl). 8135–8135. 3 indexed citations

4.

Rego, Rafaela L., Nathan R. Foster, Thomas C. Smyrk, et al.. (2009). Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. British Journal of Cancer. 102(1). 165–172. 83 indexed citations

5.

Vij, Ravi, Robert Z. Orlowski, A. Keith Stewart, et al.. (2009). PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update. Journal of Clinical Oncology. 27(15_suppl). 8537–8537. 10 indexed citations

6.

Damron, Timothy A., et al.. (1999). Lymphoma Presenting as a Soft Tissue Mass. Clinical Orthopaedics and Related Research. 360(360). 221–230. 26 indexed citations

7.

Andrieu, Nadine, Teresa Smith, Stephen W. Duffy, et al.. (1998). The effects of interaction between familial and reproductive factors on breast cancer risk: a combined analysis of seven case-control studies. British Journal of Cancer. 77(9). 1525–1536. 15 indexed citations

8.

Riou, G, et al.. (1987). C-myc PROTO-ONCOGENE EXPRESSION AND PROGNOSIS IN EARLY CARCINOMA OF THE UTERINE CERVIX. The Lancet. 329(8536). 761–763. 118 indexed citations

9.

Sancho-Garnier, H, M. Henry‐Amar, & M. H. Le. (1978). [Genetic factors in the etiology of breast cancer (author's transl)].. PubMed. 65(2). 127–30.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact